Study for combination of Pracinostat and azacitidine for treatment of high-risk myelodysplastic syndrome (MDS)

Trial Profile

Study for combination of Pracinostat and azacitidine for treatment of high-risk myelodysplastic syndrome (MDS)

Planning
Phase of Trial: Phase II

Latest Information Update: 04 May 2017

At a glance

  • Drugs Azacitidine (Primary) ; Pracinostat (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 May 2017 Planned initiation date changed from 1 Jan 2017 to 1 Jun 2017 according to a MEI Pharma media release.
    • 04 May 2017 According to a MEI Pharma media release, the company anticipates to commence the study in June 2017.
    • 06 Sep 2016 According to MEI Pharma media release, the study is anticipated to commence in first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top